Tests quarterly faricimab injections for wet age-related macular degeneration
Tests faricimab given every 12 to 16 weeks in adults with wet macular degeneration.
Plain-language title generated from the registry record
Registry title: Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
Key facts
- Where
- Hong Kong, Hong KongSee the site
- Phase
- Phase 4
Where in Hong Kong
- Department of Ophthalmology, United Chrisitian HospitalHong Kong, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital Authority, Hong Kong
- Trial code
- NCT06742307
- Record updated
- 1 October 2025
- Original description
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.Read full original descriptionShow less
Faricimab Fixed Quarterly Maintenance for Neovascular Age Related Macular Degeneration: A Prospective Case Series
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.
Inclusion: Subjects aged over 50 years, neovascular AMD with foveal involvement, both treatment-naïve and recurrent cases. There were no specific criteria for initial best-corrected visual acuity (BCVA). Only active subfoveal MNV are included, including types 1, 2, and 3.
Exclusion: eyes that received any anti-VEGF therapy in the prior six months,; concurrent macula laser (except photodynamic therapy) and ocular surgery (e.g., cataract surgery or vitrectomy) in the prior six months and the study period; eyes with other disease entities (e.g., diabetic macula oedema, retinal vein occlusions, central serous chorioretinopathy, myopicmacular neovascularisation),.